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Introduction: The 2004 version of the World Health Organization 
classification subdivides thymic epithelial tumors into A, AB, B1, 
B2, and B3 (and rare other) thymomas and thymic carcinomas (TC). 
Due to a morphological continuum between some thymoma subtypes 
and some morphological overlap between thymomas and TC, a vari-
able proportion of cases may pose problems in classification, con-
tributing to the poor interobserver reproducibility in some studies.
Methods: To overcome this problem, hematoxylin-eosin–stained 
and immunohistochemically processed sections of prototypic, “bor-
derland,” and “combined” thymomas and TC (n = 72) were studied 
by 18 pathologists at an international consensus slide workshop sup-
ported by the International Thymic Malignancy Interest Group.
Results: Consensus was achieved on refined criteria for decision 
making at the A/AB borderland, the distinction between B1, B2, 
and B3 thymomas and the separation of B3 thymomas from TCs. 
“Atypical type A thymoma” is tentatively proposed as a new type 
A thymoma variant. New reporting strategies for tumors with more 
than one histological pattern are proposed.
Conclusion: These guidelines can set the stage for reproducibility 
studies and the design of a clinically meaningful grading system for 
thymic epithelial tumors.
Key Words: Thymoma, Thymic carcinoma, Histological classifica-
tion, Diagnostic criteria.
(J Thorac Oncol. 2014;9: 596–611)
The World Health Organization (WHO) classification1,2 is the most widely used histological classification of thy-
momas and thymic carcinomas (TCs). Like classification 
schemes in most other tumors, the WHO classification assigns 
tumors to “entities” that have fundamental morphological dif-
ferences, distinguishing type A, AB, B1, B2, and B3 thymo-
mas (and rare other thymomas) from TCs. This “primate” of 
histology distinguishes the WHO histological classification 
from other schemes that separated tumors mainly on the basis 
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of tumor stage3 or tumor grade, such as the thymoma-atypical 
thymoma-TC scheme proposed by Suster and Moran.4 Despite 
of its value for the comparability of pathologic and clinical 
studies5,6 and its biological and clinical relevance,7–9 the WHO 
classification has been criticized for poor interobserver repro-
ducibility or inconsistencies in some studies.9–11 To address 
these issues at an interdisciplinary conference organized by 
the International Thymic Malignancy Interest Group (ITMIG) 
in New York, in March 2011, the participants (Appendix 1) 
agreed that the WHO classification should be maintained but 
needs refinement of histological criteria for better manage-
ment of the following problem areas that likely contribute to 
poor interobserver reproducibility:
1.  Thymomas with features intermediate between 
 prototypic subtypes (borderland cases)
2. Tumors with atypia, high mitotic activity, and necrosis
3.  Tumors showing more than one histological pattern
To achieve refined diagnostic criteria, an interdisciplin-
ary team of 18 pathologists (Appendix 2), two surgeons, and 
an oncologist reviewed prototypic and difficult-to-classify 
thymic epithelial tumors (TETs) during a consensus slide 
workshop in December 2011. The workshop was organized 
in Mannheim by ITMIG and with additional support by the 
European Society of Pathology. Descriptions given in the 
WHO classification of tumors of the thymus monograph 
(2004) were critically reviewed and revisions discussed 
by the panel. Two strategies were followed to better convey 
 agreed-upon criteria. First, there was consensus to replace the 
“narrative style” of the WHO classification by tables that list 
major (indispensable) and minor (typical) findings in addition 
to findings that are considered compatible with the diagno-
sis. Second, illustrations of prototypic histological findings 
were complemented by “galleries of figures” that illustrate 
 difficult-to-classify tumors at the “borderlands” between pro-
totypic cases.
MATERIALS AND METHODS
Collection and Prescreening of 
Thymoma and TC Cases
Participants were requested to submit paraffin blocks 
or sections of resection specimens of instructive (pro-
totypic, borderland [see end of this paragraph], or other 
 difficult-to-classify) cases of thymomas and TCs to the Institute 
of Pathology, University Medical Centre Mannheim. Hundred 
five specimens were received. Selection was made by PS and 
AM to exclude cases of low-technical quality and to reduce 
the number of clear-cut prototypic thymoma cases among the 
frequent thymoma subtypes, to retain a reasonable number of 
the most informative examples likely to achieve the purpose 
of the workshop, that is, to refine diagnostic criteria based on 
hematoxylin-eosin (H&E)-stained sections and immunohis-
tochemical results. By this strategy, cases with a broad mor-
phological spectrum among the different thymic tumors were 
retained. Due to our interest in borderland cases with differen-
tial diagnostic value, the series was highly selected and, there-
fore, may not be representative of all morphological variants. 
Of 72 cases that were selected for review at the consensus 
workshop, only 58 could finally be fully evaluated due to time 
restrictions. Usually, one block was chosen for each case, on 
which 11 immunohistochemical stains were performed at the 
Institute of Pathology, University Medical Centre Mannheim. 
Before the workshop, the 72 selected cases were assigned by 
PS and AM to three groups to address the spectrum of type 
A and AB thymoma (n = 29; finally evaluated: 16 type A and 
5 AB thymomas); the spectrum of B1, B2, and B3 thymoma 
(n = 27; finally evaluated: 6 B1, 16 B2, and 5 B3 thymomas); 
and the borderland between thymoma and TC (n = 16; finally 
evaluated: 7 B3 thymomas and 3 TCs). The term “borderland,” 
referred to throughout this article, is not intended to be a cat-
egory of thymoma in the proposed classification. The term 
refers to cases in which a decision between two diagnoses is 
difficult, usually because diagnostic criteria are quantitative 
rather than qualitative.
Histology and Immunohistochemistry
In addition to H&E staining, the following antibodies 
were applied on formalin-fixed, paraffin-embedded tissue 
using a routine immunoperoxidase technique:
1.  “Conventional” antibodies: Pancytokeratin (AE1/3), 
CD5 (T cells, epithelial cells of many TCs), CD117 
( epithelial cells of many TCs), TdT (immature T cells), 
desmin (myoid cells in the medulla).
2.  Antibodies to cortical epithelial cells: Beta5t (thymus 
cortex-specific proteasome subunit), prss16, and cathep-
sin V (both cortex-restricted proteases).
3.  Medullary thymic epithelial cell markers: CD40, clau-
din 4, and AIRE (autoimmune regulator). Details of 
the antibodies are given in Supplementary Table S1 
(Supplemental Digital Content 1, http://links.lww.com/
JTO/A576).
Workflow and Strategy to Achieve Consensus
A representative H&E-stained section of each case 
was presented by the submitting pathologist using a mul-
tihead microscope. Basic clinical data (age, sex, tumor 
size and stage, and myasthenia gravis status) but neither 
the original diagnosis nor the information whether a given 
case was considered prototypic or difficult-to-classify by 
the submitting panelist were provided. The 18 participating 
pathologists were asked (1) to allocate each case to one of 
the WHO thymoma types or to the TC category, (2) to iden-
tify difficult-to-classify cases, and (3) to roughly quantify 
histologically diverse components in cases with histological 
heterogeneity. Each participant entered his/her H&E-based 
“primary diagnosis” (WHO thymoma type or TC) on a per-
sonal data sheet. Subsequently, immunostaining results were 
presented using a digital projector, results were discussed, 
and then each participant entered his/her “final diagnosis” 
on his/her data sheet. The “consensus diagnosis,” that is, 
the final diagnosis made by the majority of the panelists 
(always >50%), was established by voting. “Consensus rate” 
represented the percentage of cases with a given consensus 
diagnosis (e.g., type B2 thymoma) to which 100% of the 
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panelists finally agreed. Such cases (with 100% final agree-
ment among the panelist) were labeled as “prototypic” and 
all others as borderland cases. The concordance rate was the 
percentage of cases with an achieved consensus diagnosis in 
which the H&E-based primary diagnoses were in agreement 
with the consensus diagnoses (i.e., the fraction of cases of a 
given WHO type that was “correctly diagnosed” ab initio) 
(Supplementary Table S2, Supplemental Digital Content 2, 
http://links.lww.com/JTO/A577).
Consensus on Major and Minor Diagnostic 
Criteria and Their Proposed Application
Following the identification of prototypic cases with 
100% consensus and related borderland cases (cases with 
incomplete consensus that underlined the necessity of refined 
diagnostic criteria), the panel members compared prototypic 
cases of different histological types at the multihead micro-
scope to identify histological and (possible) immunohisto-
chemical “major criteria” that were either consistently present 
or consistently absent in the prototypic cases of a given his-
tological category. In terms of application, major criteria are 
features that are either an absolute requirement or an abso-
lute contraindication for a given diagnosis. Minor criteria are 
features that may be typical, common, rare, or even excep-
tional for a given tumor entity and thus are supportive but not 
required for diagnosis. As an example, the diagnosis of type 
B1 thymoma requires the presence of “thymus-like architec-
ture throughout,” including medullary islands and cortical 
cytology (implying a high density of thymocytes and a low 
density of epithelial cells), as well as the absence of clustered 
epithelial cells, while Hassall’s corpuscles and a “large lobular 
growth pattern” are typical (and often helpful) but dispensable 
minor criteria.
Gallery Approach
As morphological criteria are often not categorical 
variables but form a continuum,4 the description of major 
and minor diagnostic criteria may not be able to resolve all 
diagnostic problems in borderland cases. Therefore, we pro-
duced agreed upon but admittedly arbitrary galleries of 
images to visually depict the spectrum, for example, relatively 
 epithelial-rich B1 thymoma compared with the relatively 
 epithelial-poor B2 thymoma.
RESULTS
Ad hoc Reproducibility
In approximately 85% of cases, overall there was 
full agreement between the H&E-based primary diag-
noses and the consensus diagnoses. Discrepancies con-
cerned borderlands between type A and AB thymomas 
(16% disagreement), B1 and B2 thymomas (15% disagree-
ment), and between B3s and TCs (39% disagreement, 
but with too low a number of cases to draw conclusions). 
Immunohistochemistry improved diagnosis mainly at 
the type A versus AB borderland. Details are given in 
Supplementary Table S2 (Supplemental Digital Content 2, 
http://links.lww.com/JTO/A577).
Spectrum of Type A and AB Thymoma
Type A thymoma.
Agreed-upon “major/indispensible” criteria and “minor/ 
typical” criteria are given in Table 1 for “conventional” (non-
atypical) type A thymomas that were tentatively separated 
from the rare “atypical type A thymomas” on the basis of 
mitotic activity and coagulative necrosis (see below). In con-
trast to the descriptions in the WHO classification,2 it was 
found that lack of reticulin fibers (or collagen IV expression) 
did not reliably distinguish type A from B3 thymomas. Lack 
of cortex-specific immunohistochemical markers favors a 
diagnosis of type A thymoma (Table 1). The broad morpho-
logical spectrum of conventional type A thymoma is depicted 
in Figure 1 (Supplementary Fig. S1, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A578).
The new concept of atypical type A thymoma.
This concept emerged during multidisciplinary discus-
sions in New York and based on the case review in Mannheim. 
Although the term “benign” was used in the 2004 WHO clas-
sification in the discussion of type A thymoma,2 it is well docu-
mented that even type A thymomas can present in advanced 
stages including metastasis indicating that all thymomas are 
malignant, although to a variable extent.12,13 Seven of the 16 
type A thymomas studied were labeled as an “atypical” variant. 
Agreed criteria of “atypia” were increased mitotic activity (4 or 
more per 10 high power field) and “true” (coagulative) tumor 
necrosis (in contrast to ischemic or biopsy-induced necrosis) 
(Fig. 2). Other criteria (e.g., hypercellularity, enlarged hyper-
chromatic nuclei, large nucleoli, increased Ki67 index, and 
extent of atypical areas) were difficult to quantify or could not 
be agreed upon. Recent articles14,15 have addressed the issue of 
atypical type A thymoma, and the latter authors15 suggest that 
necrosis may predict aggressiveness. Although the concept was 
TABLE 1.  Major and Minor Criteria of “Conventional” 
Type A Thymomas
Major criteria
  Spindled and/or oval-shaped tumor cells lacking nuclear  
 atypia (see text)
  Paucitya or absence of immature, TdT(+) thymocytes throughout the  
 tumor
Minor criteria
  Occurrence of rosettes and/or subcapsular cysts (to be distinguished  
 from PVS)
  Presence of focal glandular formations
  Pericytomatous vascular pattern
  Paucity or absence of PVS contrasting with presence of abundant  
 capillaries
  Lack of Hassall’s corpuscles
  Complete or major encapsulation
  Expression of CD20 in epithelial cells; absence of cortex-specific  
 markersb
aPaucity implies no (immature) lymphocyte-rich regions with dense,  “impossible-
to-count” TdT(+) lymphocytes; or at most 10% tumor regions with moderate (see text) 
immature lymphocyte counts (Fig. 2).
bBeta5t, PRSS16, and cathepsin V by immunohistochemistry (IHC).
PVS, perivascular space.
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FIGURE 1.  Spectrum of common histological patterns of conventional World Health Organization type A thymomas. Often, several 
patterns occur in the same tumor. Spindle cell pattern (A), microcystic (B), resetting (C), hemangiopericytoma like (D), glandular/
adenoid (E), mucoid (F), whorls forming (G), and synovial sarcoma-like pattern (H). For rare other patterns of type A thymoma, see 
Supplementary Figure S1 (Supplemental Digital Content 3, http://links.lww.com/JTO/A578) (hematoxylin-eosin, ×100 or ×200).
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considered, a division of type A thymoma into new entities, that 
is, A1, A2, and A3 subtypes (analogous to the type B lineage), 
was rejected due to a lack of available convincing data.
Type A versus AB thymoma.
The imprecise WHO definition of AB thymomas as 
“organotypic thymic epithelial neoplasms composed of a mix-
ture of lymphocyte-poor type A thymoma component and a 
more lymphocyte-rich type B-like component …” may explain 
the variable frequencies reported for type A (5–30%) thymo-
mas in different series.16 Immunohistochemistry showed that 
epithelial cells of AB thymomas express both cortical and 
medullary markers in an intermingled pattern, whereas type 
A thymomas lack cortical markers.17 Independent of this dif-
ference between type A and AB thymomas, type A thymomas 
should harbor no or only few TdT+ T cells (easy to count) 
(grade 1) or a moderate amount of TdT+ T cells (I could count 
if I had to) (grade 2) in 10% or less of a given biopsy (Fig. 3). 
Moderate numbers of TdT+ T cells above the arbitrary 10% 
threshold in available biopsies or any area with abundant 
(impossible to count) TdT+ T cells (grade 3 by number of 
TdT+ T cells) would favor a diagnosis of AB thymoma over 
type A thymoma. Diagnostic criteria distinguishing type A 
and AB thymoma are compared in Table 2.
Type A versus spindle cell B3 thymoma.
Prominent and abundant perivascular spaces (PVSs) 
would strongly favor a diagnosis of type B3 thymoma, whereas 
uniform nuclei, abundance of capillary vessels, rosette forma-
tion, cystic spaces, and epithelial expression of CD20 would 
favor type A thymoma. Nevertheless, distinction between 
atypical type A thymoma and spindle cell B3 thymoma can be 
more difficult because nuclear atypia is present in both, and 
immunohistochemical studies may be required.
Type AB versus micronodular thymoma.
A minor component of micronodular thymoma (MNT) 
with lymphoid stroma18–20 is a frequent finding in type A and 
AB thymoma. To distinguish AB thymoma from MNT, it is 
necessary to identify immature TdT+ T cells in a background 
of epithelial cells (which is the defining feature of AB thy-
momas) and the absence of an epithelial cell-free lymphoid 
stroma (which would qualify the case as MNT) (Fig. 4).
Type AB versus B1 thymoma.
This rare differential diagnostic challenge is discussed 
below.
Spectrum of Type B Thymomas
There was consensus that subdivision of B thymomas 
into B1, B2, and B3 subtypes should be maintained, consider-
ing (1) the unique “thymus-like” structure of B1 thymomas; 
(2) the distinct histology of type B3 thymomas; and (3) the 
more aggressive behavior of B2 compared with B1 thymo-
mas.6,21–23 Nevertheless, type B thymomas apparently repre-
sent a continuum from B1 to B3 thymomas which show a 
spectrum of lymphocyte to epithelial predominance: the bor-
derlands between them contribute to the suboptimal interob-
server reproducibility of the WHO classification.10,11,16
Distinguishing B1 thymomas from B2 thymomas.
B1 thymomas are consistently lymphocyte-rich, 
 epithelial-poor tumors that closely mimic normal thymus at 
both low and high magnification. A “sine qua non feature” of 
B1 thymomas is presence of prominent “medullary islands” 
(Fig. 5) that contain epithelial cells with or without Hassall’s 
corpuscles; a majority of mature, TdT(–) T cells; and scattered 
CD20+ mature B cells. Desmin+ myoid cells and AIRE+ med-
ullary epithelial cells are inconsistently present. Medullary 
islands can also occur in B2 thymoma (Fig. 6). PVS and abun-
dant TdT+ T cells occur in both B1 and B2 thymomas, but 
PVSs are often inconspicuous in B1 thymomas. Therefore, the 
distinguishing features of B2 thymomas are (1) increased num-
ber of epithelial cells compared with normal thymus often visi-
ble at low magnification and (2) epithelial cell clusters (defined 
FIGURE 2.  Atypical type A thymoma. A, Pulmonary metastasis of type A thymoma (hematoxylin-eosin [H&E], ×50). B, Spindle 
cell type A thymoma with comedo-type necrosis (H&E, ×200). C, Mitotic activity in a more epithelioid area (H&E, ×400).
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FIGURE 3.  Type A thymoma and borderland to AB thymoma. A, Almost lymphocyte-free type A thymoma. A′, Serial section 
with only single TdT+ immature T cells. B and C, Type A thymomas with low (easy to count) numbers of lymphocytes.  
B′ and C′, Serial sections showing TdT+ immature T cells. D and D′, Thymoma at the borderland between A and AB with focal, 
moderate (could count if I had to) number of TdT+ T cells. By definition, thymomas with moderate numbers of TdT+ T cells in 
>10% are counted among type AB thymomas. E and E′, Type AB thymoma with a high number of immature T cells (impossible 
to count). Any tumor area with such a high number of TdT+ T cells is incompatible with a diagnosis of type A thymoma  
(A–E,  hematoxylin-eosin, ×200; A′–E′, serial sections, TdT expression, immunoperoxidase, ×200).
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as at least three contiguous epithelial cells) (Supplementary 
Fig. S2, Supplemental Digital Content 4, http://links.lww.com/
JTO/A579). Nuclear size of epithelial cells is not a helpful 
distinguishing feature. On immunostaining, the keratin+ epi-
thelial cell network in B1 thymomas resembles that of normal 
thymus, whereas the network of epithelial cells in B2 thymo-
mas is significantly denser (Fig. 7). The differential diagnosis 
between type B1 and B2 thymoma is highlighted in Table 3.
Distinguishing B1 thymomas from AB thymomas.
Like B1 thymomas, AB thymomas can be lymphocyte 
rich and can show medullary islands. Nevertheless, Hassall’s 
corpuscles are almost always absent, while they occur in 50% 
of B1 thymomas. Epithelial cells inside lymphocyte-rich areas 
of AB thymomas have a spindled or oval morphology. Rarely, 
the lymphocyte-rich areas in AB thymomas may mimic B1 
thymomas. In such cases, distinguishing features are bland, 
spindled tumor cells, even in less than 10% of a TdT+ T 
 cell-rich tumor, and CD20 expression in epithelial tumor cells 
that is found in 50% of AB thymomas but not B1 thymomas.
Distinguishing B2 thymoma from B3 thymoma.
As a “rule of thumb” H&E-stained B2 and B3 thymomas 
give a “blue” versus “pink” impression, respectively, due to the 
prominent T cells in B2 versus B3 thymomas. Nevertheless, 
there are borderland cases that defy classification by descrip-
tion and are depicted here in an agreed-upon gallery as either 
B2 or B3 cases (Fig. 8) (Supplementary Fig. S3, Supplemental 
Digital Content 5, http://links.lww.com/JTO/A580). Previously 
described distinguishing criteria such as PVS and nuclear size 
are not helpful for this distinction.
Distinguishing Thymoma from TC
In general, TCs show the same histological features 
as analogous extra-thymic carcinomas (Table 4).1,2,24–27 
Nevertheless, distinction of B3 thymoma and thymic squa-
mous cell carcinoma (TSCC) may be difficult in a small per-
centage of cases. B3 thymomas typically show lobular growth, 
conspicuous PVS, minor/moderate nuclear atypia, lack of 
intercellular bridges, presence of TdT+ immature T cells, and 
lack of expression of CD5, CD117, GLUT1, and MUC1 in 
neoplastic epithelial cells.28–31 However, the following equivo-
cal situations were felt to need clarification.
Histologically typical B3 thymomas with epithelial 
 expression of CD5, CD117, MUC1, or GLUT1.
Based on the consensus about the overriding importance 
of “conventional histology” and despite the expression of 
CD5, CD117, MUC1, or GLUT1, expression of these mark-
ers in an otherwise typical B3 thymoma should not change the 
diagnosis to TC.
Histologically typical B3 thymomas but with  
absence of TdT+ T cells.
Focal absence of TdT+ T cells can occur in conventional 
B3 thymoma as illustrated in the 2004 WHO classification (p. 
165).2 Therefore, tumors that lack TdT+ T cells in the avail-
able histological material but otherwise show features of typi-
cal B3 thymomas and CD5/CD117 negativity should be called 
B3 thymomas.
 “B3 thymoma-like tumors” with expression of  
CD5 and/or CD117 and lack of TdT+ T cells.
Two such previously undescribed tumors were 
reviewed. They showed no major atypia and no intercellular 
bridges, and the patients did not have myasthenia gravis. In 
the absence of two features of TSCC (clear-cut nuclear atypia 
and intercellular bridges) and lack of an important feature of 
B3 thymomas (TdT+ T cells), these tumors were tentatively 
labeled as “B3/TSCC borderline TETs” (Fig. 9). If a compa-
rable case would show relevant atypia, a diagnosis of “TSCC 
with organoid features” was considered the more appropriate 
designation (Fig. 10).
Borderland between “thymoma with anaplasia” and TC.
Anaplasia occurs in rare B2 and B3 thymomas. It is 
usually a focal phenomenon and the tumors show main-
tained “organotypic” features, such as TdT+ T cells, PVSs, 
lobular growth pattern, and absence of CD5/ CD117 expres-
sion. Such tumors should be labeled as “B2 (or B3 or other) 
thymoma with anaplasia” according to the WHO classifi-
cation2 (p. 165). The clinical significance of this finding is 
not known.
Borderland between atypical type A thymoma and 
(spindle cell) TC.
As to this borderland, analysis of TdT is not helpful, as 
absence of TdT+ thymocytes does not exclude a diagnosis of 
atypical type A thymoma. Epithelial expression of CD20 is a 
potential marker of type A thymomas, but this is infrequently 
present in atypical type A thymomas. The usefulness of 
CD5, CD117, MUC1, and GLUT1 in this differential has not 
TABLE 2.  Major and Minor Histological Features 
Encountered in Type A and AB Thymomas
Type A  
Thymoma
Type AB  
Thymoma
Major criteria
  Biphasic pattern at low magnification due 
 to variable lymphocyte content
No Commona
  High epithelial cell content Yes Yes
  Spindled or oval epithelial cellsb Yes Yes
  Paucityc or absence of TdT+ T cells Yes No
  Medullary islandsd No Rarely presenta,e
Minor criteria
  Small lobular growth pattern No Rare
  Large lobular growth pattern Common Common
  Perivascular spaces Rarely 
present
Rarely present
  CD20 expression in epithelial cells Common Common
  Cortical marker expressionf No Yes
aThese features are minor criteria in type AB thymoma.
bAtypia in type AB thymoma has not been addressed so far.
cAs defined in Table 1.
dDetection of medullary islands is usually clear-cut on hematoxylin-eosin staining 
but may require immunohistochemistry (IHC), particularly when Hassall’s corpuscles 
are missing.
eIn lymphocyte-rich areas, usually with lack of Hassall’s corpuscles.
fBeta5t, PRSS16, and cathepsin V (detectable by IHC in epithelial cells within 
lymphocyte-rich areas).
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been well tested either. Nevertheless, similar to B3 thymo-
mas, morphologically classical type A thymomas should not 
be reclassified as TC only on the basis of CD117 and CD5 
expression. New “subtype-specific” markers are needed to 
study this unresolved borderland.
“Combined TETs”—abolishment of the term and new 
rules for reporting.
Taking into account that thymomas with heterogeneous 
histological features including B1, B2, and B3 components 
are very common, there was consensus that the term “com-
bined thymoma” should be abandoned (whether heterogeneity 
is identified by H&E structure alone or immunohistological 
studies is not relevant in this context). Instead, the diagno-
sis in such tumors should follow an approach analogous to 
Gleason scoring, listing all subtypes starting with the predom-
inant component; minor components should be reported with 
10% increments. Of note, AB thymoma is a distinct entity for 
which the 10% rule does not apply (see above). For scientific 
FIGURE 4.  Micronodular thymoma (MNT). A, MNT with central lymphocyte-rich area surrounded by  lymphocyte-poor epi-
thelial cells. B, Absence of epithelial cells in the  lymphocyte-rich area as shown by cytokeratin (AE1/3) immunostaining. C, TdT 
expression in the lymphocytes in the epithelial-free area of an MNT (the proportion of TdT+ cells in MNTs is highly variable, in 
the case shown here it is quite high); in type AB thymomas, TdT+ T cells are always intermingled with cytokeratin+ epithelial 
cells (A,  hematoxylin-eosin; B and C, immunoperoxidase, ×100).
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and statistical purposes, thymoma components of 0% to 10% 
can be neglected, and the respective tumor counted among 
the “pure” thymoma subtypes according to the dominant 
component.
By contrast, heterogeneous tumors that comprise a TC 
component of whatever size/percentage in addition to a thy-
moma component should be labeled as TC (specifying the 
percentage and histological type) followed by listing of the 
accompanying thymoma components (with quantitation as 
detailed above).
DISCUSSION
The consensus achieved on the revised histological crite-
ria for thymomas and TCs was based on microscopic review of a 
large collection of highly informative, often  difficult-to-classify 
cases. There was agreement to maintain the widely accepted 
WHO framework but to improve historic definitions2 and intro-
duce new terms, when appropriate, with the aim to improve 
interobserver reproducibility (to be tested). The term borderland 
is not intended to represent a proposal for a new type of thy-
moma. It should not be used for pathologic diagnosis; in this 
article, this term refers to problem cases for the panel to review 
with the intent of refining the 2004 classification. Another caveat 
concerns the selection of only one paraffin block per case for our 
analysis. This restriction was dictated by the limited time of the 
meeting but compatible with our aim to refine histological crite-
ria rather than checking the contributors’ original diagnoses. In 
face of the common histological heterogeneity of thymomas, we 
explicitly recommend extensive sampling of all thymic tumors.32
General Reproducibility
Previous reproducibility studies10,11 and meta-analyses16,22 
revealed poor agreement on the distinction between A and AB 
thymomas, between B1, B2, and B3 thymomas, and between 
B3 thymomas and TSCC. This was not the case in the slide 
workshop: agreement between the individual panelists’ 
FIGURE 5.  Prototypic type B1 thymoma. A, Organoid architecture with medullary island (MI; here without Hassall’s corpuscle) 
and preponderance of darker staining cortical area. B, TdT expression by immature T cells occurs almost exclusively in the cortical 
area. C, Cytokeratin expression (antibody AE1/3) shows a loose network of epithelial cells in the cortical and medullary areas; by 
contrast, perivascular spaces are distinctly epithelial free (Fig. 8). D, Low number of evenly spaced neoplastic thymic epithelial 
cells as highlighted by p63 staining of tumor cell nuclei (A, hematoxylin-eosin; B–D, immunoperoxidase, ×100; serial sections).
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FIGURE 6.  Hassall’s corpuscles as optional feature in type B1 and B2 thymoma. A, Hassall’s corpuscle in a lymphocyte-rich type 
B1 thymoma with almost no discernible epithelial cells. B, Hassall’s corpuscle in a more epithelial-rich type B2 thymoma with 
easily discernible neoplastic epithelial cells (hematoxylin-eosin, ×200).
FIGURE 7.  Density of epithelial cell networks and delineation of perivascular spaces (PVS) are helpful features to distinguish B1, 
B2, and B3 thymomas. A, Loose epithelial cell network and inconspicuous PVSs in B1 thymoma. B, Distinctly denser epithelial 
cell network and conspicuous PVSs in type B2 thymoma. C, Even denser epithelial cell staining in B3 thymoma (pancytokeratin 
antibody AE1/3, immunoperoxidase, ×200).
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 H&E-based thymoma diagnoses and the consensus diagnoses 
was more than 80% (Supplementary Table S2, Supplemental 
Digital Content 2, http://links.lww.com/JTO/A577). The high 
degree of ad hoc consensus suggests that poor interobserver 
reproducibility in some previous studies might have been due 
to imprecisely formulated diagnostic criteria.
New Criteria in Prototypic A and AB Thymoma
The WHO classification has been criticized9,12,13,33 for 
imprecise descriptions of A and AB thymoma and for calling 
them benign. First, there was agreement that A and AB thy-
momas are tumors of low malignant potential. Second, the 
description of A thymomas was refined by introducing immu-
nohistochemical criteria: (1) the neoplastic epithelial cells of 
A thymomas lack cortical markers (e.g., the beta5t protea-
some subunit) throughout the tumor; (2) the new criterion 
of “paucity of immature T cells” was explicitly specified in 
terms of quantity of TdT+ cells: thymomas at the A/AB bor-
derland with a more than 10% grade 2 component of TdT+ T 
cells are now classified as type AB thymomas. The proposed 
TdT grading and the 10% threshold were arbitrarily set and 
clearly need validation by clinicopathological correlation23 
in sufficiently sampled32 cases. Third, the potentially con-
fusing9 term “B-like area” is now replaced by “lymphocyte-
rich” component in AB thymomas,2 although the presence of 
cortical markers in AB thymomas17 reveals some truth in the 
original term. Fourth, the criticized9 statement given in the 
WHO classification that lymphocyte-rich areas in AB thy-
momas harbor polygonal tumor cells is replaced: tumor cells 
in such areas are, indeed, typically spindly or oval. These 
new definitions and clarifications will likely make type A 
thymoma an even rarer entity.16
TABLE 3.  Major and Minor Histological Features of Type B1 Versus B2 Thymomas
Type B1 Thymoma Type B2 Thymoma
Major criteria
  Thymus-like pattern throughout Consistently present Rarely presenta
  Medullary islands (+/–Hassall’s corpuscles) Consistently present Occasionally presenta
  Confluence of epithelial cells in cortical areasb No (like in the NT) Yes
  Absence of type A areas (even if <10%) Yes Yes
Minor criteria
  Small lobular growth pattern Rare Common
  Large lobular growth pattern Common Rare
  Perivascular spaces Commonly present Commonly present
  Keratin+c network like in NT Yes Denser than in NT
aThese features are, therefore, minor criteria of type B2 thymomas.
bDefined as at least three contiguous epithelial cells.
cOn immunostaining.
NT, normal thymus.
FIGURE 8.  Distinction between type B2 and B3 thymomas. A, B2 thymoma: typically impression of a blue staining tumor on 
hematoxylin-eosin (H&E) staining due to the high content of lymphocytes. B and C, B3 thymoma: impression of a pink staining 
tumor due to the (variable) paucity of lymphocytes and abundance of lightly eosinophilic or clear epithelial cells (H&E, ×200).
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The New Tentative Concept 
of Atpical A Thymoma
The long-held view that A thymomas are benign has 
prevented the general acceptance of aggressive type A thy-
moma variants.12–14 Based on the current series of type 
A thymomas many of which showed overt invasiveness 
and metastasis, there was agreement that the type A thy-
moma family includes a small subset of aggressive tumors. 
Nevertheless, a large unbiased cohort of randomly collected, 
clinically  well-annotated type A thymomas needs to be stud-
ied to define the frequency of atypia and to define which one 
or which profile (if any) of the candidate atypia markers will 
predict aggressiveness in this variant of type A thymoma. 
Before such data are available, further subdivision of type A 
thymoma into different entities in analogy to the B1, B2, and 
B3 paradigm appears premature.14
Refined Criteria for the Distinction 
Between B Thymoma Subtypes
Classification of B thymomas has shown poor 
reproducibility: reported percentages of B1 thymomas 
have ranged widely from 5% to 35%,16 and series with low 
percentages6,34–36 often reported a more favorable outcome 
than series with high percentages of B1 thymomas (the 
latter series may, in fact, have been “contaminated” by 
the more aggressive B2 thymomas).10,37 The current study 
found that several previously suggested distinguishing 
criteria2 are in fact shared by B1 and B2 thymomas and 
are only quantitatively different (Table 2). Nuclear size 
and atypia also did not reliably distinguish between B thy-
momas.9,38 Only two important criteria of B1 thymomas 
remained: absence of confluent epithelial cell clusters 
outside the “palisades” of PVSs and low  “thymus-like” 
epithelial cell content on H&E and keratin staining (Fig. 7; 
Supplementary Fig. S2, Supplemental Digital Content 4, 
http://links.lww.com/JTO/A579).
Most B2 and B3 thymomas are easily distinguished 
by their lymphocyte-rich (blue) and lymphocyte-poor (pink) 
microscopic appearance, respectively; however, they do 
form a continuum. Due to lack of “objective” (qualitative) 
markers, setting a threshold between them is somewhat arbi-
trary, and respective descriptions are prone to poor reproduc-
ibility. Therefore, borderland cases that were “eminently” 
attributed by consensus to either the B2 or B3 subtype 
are depicted in the B2 versus B3 gallery (Supplementary 
Fig. S3, Supplemental Digital Content 5, http://links.lww.
com/JTO/A580).
Clarifying Borderlands Between 
Thymomas and TCs
Most TCs are easily distinguished from thymomas by 
their typical differentiation, degree of atypia, and loss of 
organotypic features. Nevertheless, distinction of B3 thymo-
mas and thymomas with anaplasia from TC can be challeng-
ing. Following the principle that H&E structure “trumps” 
ancillary criteria, it was agreed that rare tumors that look like 
B3 thymomas on H&E but either express CD5/CD117 or 
lack TdT+ T cells as single “TC-associated” feature should 
be called B3 thymomas. Such tumors have indeed been 
described.39 For tumors that looked like B3 thymomas on 
H&E but showed two features of TC, namely CD5/CD117 
expression and lack of TdT+ T cells, we propose calling 
them “B3/TC borderline tumors”—in analogy to rare “grey 
zone lymphomas.”40 In case of anaplasia, we kept the WHO 
concept: anaplasia occurring against a thymoma background 
should be mentioned in the diagnosis but should not entail a 
diagnosis of TC.
As to intratumorous TdT+ T cells in TC, the WHO clas-
sification states that TC lacks TdT+ T cells. Nevertheless, 
myasthenia gravis, which appears to depend on intratumorous 
thymopoiesis,41,42 has been described even in association with 
rare sarcomas that contained TdT+ T cells43,44 showing that 
intratumorous thymopoiesis is not necessarily restricted to 
thymomas. Therefore, the rare occurrence of TdT+ T cells in 
an otherwise typical TC is not sufficient to reassign the tumor 
to the category of thymoma. Analysis of a large number of 
cases of TC for TdT+ T cells is needed to determine the fre-
quency of such cells in TC.
Thymic tumors with more than one tumor component 
are so common6,45 that we recommend modification of the 
rules for their reporting. First, we agreed that thymomas 
which are composed of different thymoma subtypes should 
no longer be called “combined thymomas.” Instead, in 
analogy to Gleason scoring, different components should 
be listed (and quantified with 10% increments) beginning 
with the predominant histology. Second, for statistical and 
study purposes, thymoma components of 10% or less in a 
thymoma can be disregarded and the given tumor classified 
according to the predominant component. The 10% thresh-
old was found to be of prognostic relevance in one previous 
TABLE 4.  Criteria for the Histological Diagnosis of TC
Major (indispensible)
  Clear-cut atypia of tumor epithelial cells with the severity typical of  
 carcinoma
  Exclusion of “thymoma with atypia and/or anaplasia” and of typical or  
 atypical carcinoids
  Exclusion of metastasis to the thymus and germ cell and mesenchymal  
 tumors with epithelial features
Minor (typical)
  Infiltrative growth pattern
  Small tumor cell nests within desmoplastic stroma
  Absence of immature, TdT+ T cells (with rare exceptions)
  Immunohistochemistry: epithelial expression of CD5, CD117; extensive  
 expression of GLUT1, MUC1a
Features compatibleb with the diagnosis of TC
  Invasion with pushing borders
  Occurrence of perivascular spaces
  Occurrence of “Hassall-like” epidermoid whorls and/or of myoid cells
  Occurrence of (usually rare) immature, TdT+ T cells
aCD5, CD117, GLUT1, and MUC1 are expressed by many nonthymic cancers.
bAlthough most of these features are “organotypic,” that is, characteristic of 
thymoma, their presence does not exclude a diagnosis of TC if major diagnostic criteria 
of TC are fulfilled.
TC, thymic carcinoma.
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study6 but needs independent reevaluation in biopsies and 
resection specimens. Third, there was consensus that the 
reporting of histologically heterogeneous thymic tumors 
comprising a carcinoma component should be different 
from the reporting of thymomas: such tumors should in the 
first place be labeled as carcinomas with listing of the pro-
portion, differentiation, and grade, followed by the list of 
the thymoma component(s) as listed above.
Open Questions and Perspectives
First, the current proposals including the “gallery 
approach” to delineate thymoma subtypes from each other 
need to be tested for interobserver reproducibility. Second, 
to define the sensitivity and specificity of the proposed new 
criteria, they need to be tested by the current panelists in 
an independent, large series of randomly selected thymo-
mas and TC. Third, multivariate analysis will be important 
to validate or adjust thresholds (e.g., the “10% rule”) or 
“re-refine” other criteria that so far are largely arbitrary, 
borrowed from the realm of lung cancer or mesothelioma 
pathology46 or based on rare historic studies.6 A more 
reproducible histological classification of thymomas and 
TCs may provide the foundation for developing a grading 
system for TETs that helps stratify tumors into clinically 
relevant, prognostic groups.2 Currently, it is an open ques-
tion whether the rare B1 and the common B2 thymomas as 
defined here are best counted among the low and interme-
diate grade TETs, respectively,6,23,34 or whether they should 
be considered members of the same grade.4 As reliable his-
tological subtyping that reflects morphological diversity 
might mirror biological diversity including the expression 
of different therapeutic targets, future studies will have to 
investigate whether the refinements proposed here improve 
prognostic stratification and the predictive power of the 
WHO classification.
ACkNOWLEDGMENTS
The International Thymic Malignancy Interest Group 
was the main sponsor of the meeting; additional funding was 
provided by the European Society of Pathology.
FIGURE 9.  B3 thymoma/thymic squamous cell carcinoma borderline thymic epithelial tumor. A, Tumor with a B3 
 thymoma-like histology on hematoxylin-eosin (H&E) with perivascular spaces and minimal atypia but without lymphoid cells. B 
and C, Expression of CD5 (B) but not of CD117, chromogranin, and CD56 (C) in neoplastic epithelial cells. D, Absence of TdT+ 
T cells (A, H&E, ×100; B–D, immunoperoxidase, ×100).
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FIGURE 10.  Thymic squamous cell carcinoma with organoid features (contributed by Prof. K. Mukai). A and B, Tumor with 
B3 thymoma-like architecture, including perivascular spaces, however with lack of lymphoid cells (absence of TdT expression, 
not shown) and with more nuclear atypia than the tumor shown in Figure 9. C and D, Moderate expression of CD5 and focal, 
strong expression of CD117 (A and B hematoxylin-eosin; C and D immunoperoxidase, ×100).
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